EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice

Georgia Kalodimou, Sylvia Jany, Astrid Freudenstein, Jan Hendrik Schwarz, Leonard Limpinsel, Cornelius Rohde iD, Alexandra Kupke iD, Stephan Becker iD, Asisa Volz, Alina Tscherne iD, Gerd Sutter iD

Viruses · 2023

DOI: 10.3390/v15051180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Georgia Kalodimou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Center for Infection Research, Federal Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic caused significant human health and economic consequences. Due to the ability of SARS-CoV-2 to spread rapidly and to cause severe disease and mortality in certain population groups, vaccines are essential for controlling the pandemic in the future. Several licensed vaccines have shown improved protection against SARS-CoV-2 after extended-interval prime-boost immunizations in humans. Therefore, in this study, we aimed to compare the immunogenicity of our two Modified Vaccinia virus Ankara (MVA) based COVID-19 candidate vaccines MVA-SARS-2-S and MVA-SARS-2-ST after short- and long-interval prime-boost immunization schedules in mice. We immunized BALB/c mice using 21-day (short-interval) or 56-day (long-interval) prime-boost vaccination protocols and analyzed spike (S)-specific CD8 T cell immunity and humoral immunity. The two schedules induced robust CD8 T cell responses with no significant differences in their magnitude. Furthermore, both candidate vaccines induced comparable levels of total S, and S2-specific IgG binding antibodies. However, MVA-SARS-2-ST consistently elicited higher amounts of S1-, S receptor binding domain (RBD), and SARS-CoV-2 neutralizing antibodies in both vaccination protocols. Overall, we found very comparable immune responses following short- or long-interval immunization. Thus, our results suggest that the chosen time intervals may not be suitable to observe potential differences in antigen-specific immunity when testing different prime-boost intervals with our candidate vaccines in the mouse model. Despite this, our data clearly showed that MVA-SARS-2-ST induced superior humoral immune responses relative to MVA-SARS-2-S after both immunization schedules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAnimalsMicePandemicsVaccinia virusVaccinationAntibodies, ViralImmunity, CellularImmunity, Humoral

Stichwörter der Autor:innen

Modified Vaccinia virus AnkaraSARS-CoV-2preclinical testingvaccinia virusvector vaccine

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
  • German Center for Infection Research (DZIF), Partner Site Munich, 85764 Oberschleißheim, Germany.
  • Institute of Virology, Philipps University of Marburg, 35043 Marburg, Germany.
  • German Center for Infection Research (DZIF), Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
  • Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
  • German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 30559 Hannover, Germany.

ORCID-Profile: Cornelius Rohde, Alexandra Kupke, Stephan Becker, Alina Tscherne, Gerd Sutter

Förderung

  • German Center for Infection Research
  • Federal Ministry of Education and Research

Zitieren

APA

Kalodimou, G., Jany, S., Freudenstein, A., Schwarz, J. H., Limpinsel, L., Rohde, C., Kupke, A., Becker, S., Volz, A., Tscherne, A., & Sutter, G. (2023). Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice. Viruses. https://doi.org/10.3390/v15051180

Vancouver

Kalodimou G, Jany S, Freudenstein A, Schwarz JH, Limpinsel L, Rohde C, et al. Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice. Viruses. 2023. doi:10.3390/v15051180

BibTeX
@article{Kalodimou2023,
  author = {Kalodimou, Georgia and Jany, Sylvia and Freudenstein, Astrid and Schwarz, Jan Hendrik and Limpinsel, Leonard and Rohde, Cornelius and Kupke, Alexandra and Becker, Stephan and Volz, Asisa and Tscherne, Alina and Sutter, Gerd},
  title = {Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15051180}
}
Kostenlos starten →